Azelastine Nasal Spray Reduces COVID-19 Infections
“`html
Azelastine Nasal Spray Shows Promise in Preventing SARS-CoV-2 Infections
Table of Contents
Published September 2,2025,at 18:15:51
Key Findings
A recent clinical trial suggests that azelastine nasal spray may considerably reduce the risk of SARS-CoV-2 infection. The study, led by Professor Robert Bals at Saarland University Medical Center, found a ample difference in infection rates between those using azelastine and a placebo group.
The trial involved 450 participants divided into two groups: 227 individuals received azelastine nasal spray three times daily, while 223 received a placebo spray, also administered three times a day, over a 56-day period. Professor bals,director of the Department of Internal Medicine V at Saarland University Medical Center,highlighted the core result: “During the observation period,2.2% of the participants in the azelastine group became infected with SARS-CoV-2; in the placebo group, it was 6.7%.”
| Group | Number of Participants | SARS-CoV-2 Infection Rate |
|---|---|---|
| Azelastine | 227 | 2.2% |
| Placebo | 223 | 6.7% |
Study Details and Methodology
The research, published in JAMA Internal Medicine (doi.org/10.1001/jamainternmed.2025.4283), was designed to assess the preventative capabilities of azelastine, an antihistamine commonly used to treat allergic rhinitis. The study’s focus on nasal governance is based on the understanding that SARS-CoV-2 initially infects cells in the nasal passages.
Azelastine’s mechanism of action may involve reducing viral entry and replication within the nasal mucosa. While traditionally known for its antihistamine properties, research suggests it also possesses antiviral effects against certain viruses. This trial aimed to determine if those effects translated to protection against SARS-CoV-2.
Implications and Future Research
These findings suggest that azelastine nasal spray could be a valuable tool in preventing SARS-CoV-2 infections, especially as new variants emerge.Its accessibility and relatively low cost make it a possibly attractive preventative option. However, it’s crucial to note that this is a single study, and further research is needed to confirm these results in larger and more diverse populations.
Future studies should investigate the optimal dosage and duration of azelastine use for preventative purposes. Researchers will also need to explore